2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W171071
    Phenylethynylcarbinol carbamate 3567-38-2 98%
    Phenylethynylcarbinol carbamate is a agent used for neurology disease. Phenylethynylcarbinol carbamate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Phenylethynylcarbinol carbamate
  • HY-W186242
    PDE4-IN-16 223500-15-0 98%
    PDE4-IN-16 (compound 27) is a PDE4 inhibitor with an IC50 value of 3.61 μM. PDE4-IN-16 can be used for the research of inflammatory diseases and central nervous system (CNS) disorders involving elevated levels of cytokines.
    PDE4-IN-16
  • HY-W200249
    Meta-methyl 4-anilino-1-Boc-piperidine 679409-60-0 98%
    Meta-methyl 4-anilino-1-Boc-piperidine is a precursor in the synthesis of a compound.
    Meta-methyl 4-anilino-1-Boc-piperidine
  • HY-W201842
    Octamylamine 502-59-0 98%
    Octamylamine is an anticholinergic and antispasmodic agent.
    Octamylamine
  • HY-W203728
    L-β-Imidazolelactic acid 14403-45-3 98%
    L-β-Imidazolelactic acid is a histidine derivative and an oxidizing agent that can trigger antioxidant effects in the brain cortex of rats.
    L-β-Imidazolelactic acid
  • HY-W205529
    RO 16-6491 free base 87235-61-8 98%
    RO 16-6491 Free base is a selective, reversible inhibitor of monoamine oxidase type B (MAO-B), exhibiting high affinity and specificity for binding sites in human frontal cortex mitochondria and platelet membranes. RO 16-6491 demonstrates a fast dissociation of bound radioactivity at 20 degrees C, indicating its dynamic binding properties. RO 16-6491 also acts as a substrate for MAO-B, suggesting that its oxidation may produce a stable intermediate responsible for its potent inhibitory effects. RO 16-6491 serves as an excellent radioligand probe for investigating the regional tissue distribution of MAO-B in various physiological and pathological states.
    RO 16-6491 free base
  • HY-W230975
    (E/Z)-Piperine 7780-20-3 98.91%
    (E/Z)-Piperine ((E/Z)-Bioperine) is an alkaloid with a pungent property. (E/Z)-Piperine shows anti-inflammation, immunomodulatory and anti-cancer, antispasmodic and anti-secretory effects. (E/Z)-Piperine demonstrates significant neuroprotective effect in Alzheimer’s disease and Parkinson’s disease.
    (E/Z)-Piperine
  • HY-W250725
    H-GLU-AMC-OH 98516-76-8 98%
    H-GLU-AMC-OH is an amino acid derivative that can be used as A fluorescent peptide substrate for the determination of aminopeptidase A enzyme activity.
    H-GLU-AMC-OH
  • HY-W263279
    (E)-Guanabenz 60329-03-5 98%
    (E)-Guanabenz ((E)-Wy-8678) is an orally active central α2-adrenoceptor agonist. (E)-Guanabenz has antihypertensive activity, acts via stimulating central α2-adrenoceptors, and reducing net sympathetic outflow into the periphery. (E)-Guanabenz also directly binds to and inhibits GADD34, and has neuroprotective activity. (E)-Guanabenz can be used for researching hypertension and Parkinson disease.
    (E)-Guanabenz
  • HY-W264038
    4-Fluorohippuric acid 366-79-0 98%
    4-Fluorohippuric acid is a major metabolite of flupirtine with research potential against pain and epilepsy.
    4-Fluorohippuric acid
  • HY-W265961
    Squoxin 1096-84-0 98%
    Squoxin (ST1859) is an antiamyloid agent that specifically binds to Aβ1-42 and prevents the aggregation and fibril formation of Aβ. Squoxin crosses the blood-brain barrier (BBB) and has anthelmintic activity and anti-inflammatory properties.
    Squoxin
  • HY-W266188
    Decanoic acid-13C 84600-66-8 98%
    Decanoic acid-13C is the 13C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy.
    Decanoic acid-13C
  • HY-W269511
    NW-1689 405-85-6 98%
    NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM is a drug used to treat Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research.
    NW-1689
  • HY-W275048
    MAO-A inhibitor 3 35924-44-8 98%
    MAO-A inhibitor 3 (Compound 360) is a MAO-A inhibitor, with IC50 of >100 μΜ. MAO-A inhibitor 3 can be used to study neurological disorders.
    MAO-A inhibitor 3
  • HY-W278072
    Calcium Channel antagonist 1 43067-01-2 98%
    Calcium Channel antagonist 1 is an antagonist of Calcium Channel Calcium Channel antagonist 1 has the potential for the research of neurology disease.
    Calcium Channel antagonist 1
  • HY-W296398
    5-Bromo-N,N-dimethyltryptamine 17274-65-6 98%
    5-Bromo-N,N-dimethyltryptamine, an active metabolite, is an antidepressant and sedative drug lead. 5-Bromo-N,N-dimethyltryptamine shows strong affinity towards 5-HT1A, 5-HT2B, 5-HT6, and 5-HT7.
    5-Bromo-N,N-dimethyltryptamine
  • HY-W309130
    (S)-Tolterodine 124937-53-7 98%
    (S)-Tolterodine is a muscarinic acetylcholine receptor (mAChR) inhibitor, with an IC50 of 588 nM.
    (S)-Tolterodine
  • HY-W325509
    AH 8532 786581-55-3 98%
    AH 8532, an opioid, possesses anti-nociceptive effect and inhibits writhing induced by phenylquinone, with a ED50 of 16 mg/kg in mice orally.
    AH 8532
  • HY-W329175
    N-Despropyl Ropinirole 106916-16-9 98%
    N-Despropyl Ropinirole (SKF-104557) is an active metabolite of the dopamine D2 receptor agonist Ropinirole (HY-B0623). N-Despropyl Ropinirole is a full agonist at human D2 and D3 receptors. N-Despropyl Ropinirole is a partial agonistof the hD4 receptor.
    N-Despropyl Ropinirole
  • HY-W331017
    1-Hexacosanoyl-sn-glycero-3-phosphocholine 1213783-80-2 98%
    1-Hexacosanoyl-sn-glycero-3-phosphocholine (26:0 Lyso PC) is a long-chain fatty acid. 1-Hexacosanoyl-sn-glycero-3-phosphocholine can be used as a biomarker for X-linked adrenoleukodystrophy (ALD) in mice.
    1-Hexacosanoyl-sn-glycero-3-phosphocholine
Cat. No. Product Name / Synonyms Application Reactivity